ADVANZ PHARMA Corp. Announces Third Quarter 2019 Results

Third quarter 2019 revenue of $120 million Third quarter 2019 net loss of $119 million Third quarter 2019 Adjusted EBITDA1 of $56 million Generated cash flows from operating activities of $151 million